HOME >> BIOLOGY >> NEWS
Jefferson scientists use gene therapy to reverse heart failure in animals

(PHILADELPHIA) Heart researchers at the Center for Translational Medicine at Jefferson Medical College have used gene therapy to reverse heart failure in animals. In addition, they found that this gene therapy strategy had "unique and additive effects" to currently used, standard heart failure drugs called beta-blockers.

Reporting in the American Heart Association journal Circulation, researchers led by Walter J. Koch, Ph.D., director of the Center for Translational Medicine and the George Zallie and Family Laboratory for Cardiovascular Gene Therapy in the Department of Medicine at Jefferson Medical College of Thomas Jefferson University in Philadelphia, used a virus to carry the gene for a protein, S100A1, into the heart cells of rats with heart failure. The virus expressed the S100A1 gene only in heart cells and not in other organs, essentially making it a tailored therapy. After 18 weeks, those animals that received the gene therapy had significantly improved heart function compared to animals that did not receive the treatment.

Specifically, the Koch team, including Patrick Most, M.D., and Joseph Rabinowitz, Ph.D., also in Jefferson's Center for Translational Medicine, experimentally produced heart failure in the animals, which is characterized by a dramatic reduction in the heart's pumping ability. The scientists then delivered a modified adeno-associated virus (AAV) that contained the S100A1 gene to the heart's coronary arteries with the help of a novel heart-specific "gene promoter" that enabled the gene to be present only in heart cells.

The rats with heart failure were then followed for another two months, when their heart pumping function was monitored again. The animals that received the gene therapy had significantly better heart-pumping abilities compared to the pre-gene therapy level, and overall, the S100A1-treated rats had improved heart health. The researchers found this in both individual heart cells and in the whole
'"/>

Contact: Steve Benowitz
steven.benowitz@jefferson.edu
215-955-5291
Thomas Jefferson University
23-May-2007


Page: 1 2 3

Related biology news :

1. Jefferson scientists patent dramatically improves
2. Marker predicts pancreatic cancer outcome after surgery, Jefferson surgeon finds
3. Tiny genes may increase cancer susceptibility, Jefferson scientists find
4. Jefferson researchers discovery may change thinking on how viruses invade the brain
5. Jefferson scientists identify protein key to breast cancer spread, potential new drug target
6. Jefferson scientists find rabies-based vaccine could be effective against HIV
7. Jefferson scientists uncover gene mutation that cuts colon polyps, may suppress cancer
8. Targeting the adrenal gland could be key strategy against heart failure, Jefferson scientists show
9. Jefferson scientists find guardian genes choices crucial to stopping cancer process
10. Jefferson researchers uncover new way nature turns genes on and off
11. Jefferson researchers develop combined procedure for uterine preservation in treating fibroids

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/8/2017)... -- Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... its quarter and year ended December 31, 2016. ... million compared to $6.9 million in the same quarter last ... $0.6 million compared to $2.6 million in the fourth quarter ... was $0.5 million, or $0.02 per diluted share, which compares ...
(Date:2/8/2017)... Feb. 7, 2017 The biometrics market ... the confluence of organizations, desires to better authenticate ... systems (password and challenge questions), biometrics is quickly ... systems. The market is driven by use cases, ... consumer and enterprise uses cases, with consumer-facing use ...
(Date:2/7/2017)... Minn. , Feb. 7, 2017   MedNet ... supports the entire spectrum of clinical research, is pleased ... iMedNet , its innovative, highly flexible and award ... iMedNet customers. iMedNet is a proven ... provides Electronic Data Capture (EDC), but also delivers an ...
Breaking Biology News(10 mins):
(Date:2/28/2017)... ... February 28, 2017 , ... Patient travel ... and expertise. Colpitts Clinical Trial Travel and Expense , a division of ... unique need within the biotechnology and pharmaceutical industries in the United States, Europe, ...
(Date:2/28/2017)... , ... February 28, 2017 , ... Over 8,000 recognized ... In a new educational webinar on March 7, DrugDev will gather international ... in this especially difficult area. , Webinar: Overcoming the Challenges of Rare Disease ...
(Date:2/28/2017)... Diego, California (PRWEB) , ... February 28, 2017 ... ... and supports high-growth, high-impact life science and biotechnology companies today announced it ... entrepreneurial communities, will be based out of Durham, NC and will begin work ...
(Date:2/28/2017)... RepliCel Life Sciences Inc. (OTCQB:REPCF) (TSXV:RP) (FRA:P6P2) ("RepliCel" or ... unique biologic products for pattern baldness and thinning hair, ... announced it has recently signed agreements with two European ... RepliCel to get the Company,s commercial-grade RCI-02 dermal injector ... ...
Breaking Biology Technology:
Cached News: